Adherium

Adherium Equity Ratio

The Equity Ratio of Adherium (ADR.AX) as of Nov 2, 2026 is -28.27 %. In the previous year, Equity Ratio was -135.50 % — a change of -79.14% (higher).

Equity Ratio

-28.27 %

YoY

-79.14%

Last updated:

Equity Ratio of Adherium is 2026 -28.27 % . Equity Ratio of Adherium was 2025 -135.50 % . It decreases by -79.14% higher compared to the previous year.

The Adherium Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2019
36.99 AUD
Jan 1, 2020
50.37 AUD
Jan 1, 2021
82.37 AUD
Jan 1, 2022
64.89 AUD
Jan 1, 2023
72.66 AUD
Jan 1, 2024
65.54 AUD
Jan 1, 2025
-135.50 AUD
Jan 1, 2026
-28.27 AUD
The Adherium Equity Ratio history
YEAREquity RatioYoY
-28.27 %-79.14%
-135.50 %-306.73%
65.54 %-9.79%
72.66 %+11.98%
64.89 %-21.22%
82.37 %+63.52%
50.37 %+36.19%
36.99 %-55.76%
83.61 %-7.60%
90.49 %-4.57%
94.83 %+2.04%
92.93 %+19.72%
77.62 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Adherium Stock analysis

What does Adherium do? Adherium Ltd develops and supplies connected medical devices and respiratory medications for patients, pharmaceutical companies, healthcare providers, and contract research organizations. The company generates revenue through its Hailie sensor technology and cloud-based data platform, which provides real-time feedback on patients' use of inhaled medication. The Hailie Remote Patient Management (RPM) Solution, Hailie Sensors, and Hailie Solution are key products sold to healthcare providers, payers, and pharmaceutical companies. These solutions enable optimal management of severe asthma and COPD, reduce healthcare costs, and offer remote monitoring capabilities for patients and physicians. The Hailie Sensor technology wraps around inhalers and connects via Bluetooth to capture medication use data, which is transmitted to the cloud-based Hailie platform. This platform delivers real-time feedback to patients through the Hailie app and to physicians via the Hailie portal. The company's focus on patient medication adherence and remote monitoring drives demand from healthcare providers seeking to improve treatment outcomes and from pharmaceutical companies aiming to enhance patient engagement with their respiratory medications. Adherium's products target segments including patients with severe asthma and COPD, healthcare providers managing chronic conditions, payers interested in cost reduction, and pharmaceutical companies developing respiratory medications. The company's revenue model centers on selling its sensor technology, cloud platform access, and integrated RPM solutions to these key segments, leveraging FDA-cleared devices to ensure compliance and reliability in healthcare settings. Adherium is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Adherium stock

Equity Ratio of Adherium is -28.27 % in 2026.

Equity Ratio of Adherium changed from -135.50 % to -28.27 %, representing a -79.14% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Adherium since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Adherium with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Adherium

All Key Metrics — Adherium